Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635
| KPTI Stock | USD 0.78 0.03 3.70% |
Under 61% of Karyopharm Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Karyopharm Therapeutics suggests that many traders are alarmed. Karyopharm Therapeutics' investing sentiment shows overall attitude of investors towards Karyopharm Therapeutics.
Karyopharm |
Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted a stock option to purchase an aggregate of 101,250 shares of Karyopharms common stock and an aggregate of 108,540 restricted stock units to four newly-hired employees. These RSU awards were granted as of December 31, 2024 pursuant to the Companys 2022 Inducement Stock Incentive Plan, as amended, as inducemen
Read at finance.yahoo.com
 |
Karyopharm Therapeutics Fundamental Analysis
We analyze Karyopharm Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Karyopharm Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Karyopharm Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Asset
Total Asset Comparative Analysis
Karyopharm Therapeutics is currently under evaluation in total asset category among its peers. Total Asset is everything that a business owns. It is the sum of current and long-term assets owned by a firm at a given time. These assets are listed on a balance sheet and typically valued based on their purchasing prices, not the current market value.
Karyopharm Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Karyopharm Therapeutics stock to make a market-neutral strategy. Peer analysis of Karyopharm Therapeutics could also be used in its relative valuation, which is a method of valuing Karyopharm Therapeutics by comparing valuation metrics with similar companies.
Peers
Karyopharm Therapeutics Related Equities
| NUVB | Nuvation Bio | 11.58 | ||||
| MREO | Mereo BioPharma | 9.06 | ||||
| CTMX | CytomX Therapeutics | 6.60 | ||||
| RLYB | Rallybio Corp | 6.32 | ||||
| BLUE | Bluebird Bio | 5.64 | ||||
| GOSS | Gossamer Bio | 5.15 | ||||
| GBIO | Generation Bio | 3.60 | ||||
| NVCT | Nuvectis Pharma | 3.53 | ||||
| KRON | Kronos Bio | 3.09 | ||||
| ABOS | Acumen Pharmaceuticals | 2.70 | ||||
| ASMB | Assembly Biosciences | 1.98 | ||||
| PMVP | Pmv Pharmaceuticals | 1.31 | ||||
| AGIO | Agios Pharm | 1.10 | ||||
| GLUE | Monte Rosa | 0.84 | ||||
| REPL | Replimune | 0.48 | ||||
| MRSN | Mersana Therapeutics | 0.71 | ||||
| XFOR | X4 Pharmaceuticals | 1.33 | ||||
| LYRA | Lyra Therapeutics | 4.55 | ||||
| HOOK | Hookipa Pharma | 4.62 |
Complementary Tools for Karyopharm Stock analysis
When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |